We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced that the FDA has approved its kinase inhibitor, Vijoice (alpelisib), for the treatment of patients aged two years and above with severe manifestations of PIK3CA-Related Overgrowth Spectrum (“PROS”), requiring systemic therapy.
Per the company, following the nod, Vijoice became the first FDA-approved therapy to treat PROS, which includes rare conditions where overgrowths and blood vessel anomalies occur.
The approval was made on an accelerated basis, with continued approval contingent on verification of clinical benefit from confirmatory evidence.
The FDA approval was based on real-world data from the EPIK-P1 study, which evaluated Vijoice in select patients with severe manifestations of PROS. Data from the same showed that treatment with Vijoice led to reduction in the size of PROS lesions and improvement of PROS-related signs and symptoms in the given patient population.
Shares of Novartis have gained 0.8% so far this year compared with the industry’s growth of 3.7%.
Image Source: Zacks Investment Research
Per the company, approximately 14 people per million are diagnosed with PROS. Until now, the only treatment options available for such patients were surgical or interventional radiology procedures. Hence, the approval of Vijoice is likely to offer a better treatment trajectory and outcomes for the given patient population.
Alpelisib is also approved under the brand name Piqray in the United States, the European Union and other countries. Piqray, in combination with fulvestrant, is approved to treat men and postmenopausal women with PIK3CA-mutated, HR+/HER2- locally advanced or metastatic breast cancer.
The FDA recently approved Novartis’ targeted radioligand therapy, Pluvicto, for the treatment of progressive PSMA-positive metastatic castration-resistant prostate cancer.
Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug, Cosentyx; cardiovascular drug, Entresto; gene therapy, Zolgensma; its oncology portfolio and the launch of Kesimpta continue to boost performance.
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank of #3 (Hold).
Better-ranked stocks in the healthcare sector include Innoviva, Inc. (INVA - Free Report) , Collegium Pharmaceutical, Inc. (COLL - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) . While Innoviva and Collegium Pharmaceutical sport a Zacks Rank #1 (Strong Buy), Voyager Therapeutics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Innoviva’s earnings has been revised 20.5% upward for 2022 and 27.9% upward for 2023 over the past 60 days. The INVA stock has rallied 13.7% year to date.
Earnings of Innoviva surpassed estimates in each of the trailing four quarters.
Collegium Pharmaceutical’s earnings estimates have been revised 51.9% upward for 2022 and 66.2% for 2023 over the past 60 days. The COLL stock has gained 7.5% year to date.
Earnings of Collegium Pharmaceutical surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 231.7% year to date.
Earnings of Voyager Therapeutics surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
Novartis AG (NVS - Free Report) announced that the FDA has approved its kinase inhibitor, Vijoice (alpelisib), for the treatment of patients aged two years and above with severe manifestations of PIK3CA-Related Overgrowth Spectrum (“PROS”), requiring systemic therapy.
Per the company, following the nod, Vijoice became the first FDA-approved therapy to treat PROS, which includes rare conditions where overgrowths and blood vessel anomalies occur.
The approval was made on an accelerated basis, with continued approval contingent on verification of clinical benefit from confirmatory evidence.
The FDA approval was based on real-world data from the EPIK-P1 study, which evaluated Vijoice in select patients with severe manifestations of PROS. Data from the same showed that treatment with Vijoice led to reduction in the size of PROS lesions and improvement of PROS-related signs and symptoms in the given patient population.
Shares of Novartis have gained 0.8% so far this year compared with the industry’s growth of 3.7%.
Image Source: Zacks Investment Research
Per the company, approximately 14 people per million are diagnosed with PROS. Until now, the only treatment options available for such patients were surgical or interventional radiology procedures. Hence, the approval of Vijoice is likely to offer a better treatment trajectory and outcomes for the given patient population.
Alpelisib is also approved under the brand name Piqray in the United States, the European Union and other countries. Piqray, in combination with fulvestrant, is approved to treat men and postmenopausal women with PIK3CA-mutated, HR+/HER2- locally advanced or metastatic breast cancer.
The FDA recently approved Novartis’ targeted radioligand therapy, Pluvicto, for the treatment of progressive PSMA-positive metastatic castration-resistant prostate cancer.
Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug, Cosentyx; cardiovascular drug, Entresto; gene therapy, Zolgensma; its oncology portfolio and the launch of Kesimpta continue to boost performance.
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank of #3 (Hold).
Better-ranked stocks in the healthcare sector include Innoviva, Inc. (INVA - Free Report) , Collegium Pharmaceutical, Inc. (COLL - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) . While Innoviva and Collegium Pharmaceutical sport a Zacks Rank #1 (Strong Buy), Voyager Therapeutics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Innoviva’s earnings has been revised 20.5% upward for 2022 and 27.9% upward for 2023 over the past 60 days. The INVA stock has rallied 13.7% year to date.
Earnings of Innoviva surpassed estimates in each of the trailing four quarters.
Collegium Pharmaceutical’s earnings estimates have been revised 51.9% upward for 2022 and 66.2% for 2023 over the past 60 days. The COLL stock has gained 7.5% year to date.
Earnings of Collegium Pharmaceutical surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 231.7% year to date.
Earnings of Voyager Therapeutics surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.